US Edition
Balancing Cost, Coverage, and Clinical Value in First-Line Multiple Myeloma Care: Emilie Aschenbrenner, PharmD, BCOP
Summary by ajmc.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Balancing Cost, Coverage, and Clinical Value in First-Line Multiple Myeloma Care: Emilie Aschenbrenner, PharmD, BCOP
Emilie Aschenbrenner, PharmD, BCOP, discusses how integrating CD38-targeted therapies into first-line treatment for transplant-ineligible multiple myeloma requires balancing clinical benefit, cost, and insurance coverage.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium